Case File
efta-efta00299761DOJ Data Set 9OtherBioReference
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00299761
Pages
4
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
BioReference
PRELIMINARY
L Aar,,, ,: ATC: 9 I ES
C/PKO
ORSHER, STUART
C3070 - STUART ORSHER, M.D.
9 EAST 79TH ST,
NEW YORK, NY 18021
Acct
P.
PO IIIII
EPSTEIN, JEFFREY
D08: 41/20/1953 Age:64 V skate i
U/FL:
Bed:
RM:
•
Patient 10:
Address:9 EAST 71ST STREET.
INW YORK, HY 10021
P:
Dotes: NON FASTING
NOTE: SST tube submitted was inadequately spun. Serum was found to
contain ReCs. Certain tests, e.g. Glucose, nay be decreased while
ethers e.g. Potassium or LOH may be elevated.
Specimen I' 104659439
Date Of APport.,,f44414NOP-65:29
Date Collected: 09/19/2017 08:57
Date Received: 09/15/2017 23:06
Ateth MiltriCO EOS tern rime
CLINICAL REPORT
(Nay not contain all abnormal results: narrative results say not have abnormal
Clinical Abnormalities Summary:
flags. Please review entire report.)
Cholesterol
224 HI
Triglycerides
646 HI
HDL CHOL., DIRECT
29 LO
HEN as % of
13 •
rhol/HOL Ratio
7.7
NON-HDL
115 HI
Cholesterol
CHOLESTEROL
HEP. A Ab., TOTAL
Reactive
HEP. B SURF. A3.
Reactive
250H, VITAMIN D
31.5 LO
PTH(3), INTACT
106.0 HI
Albumin
Calcium --
4.7
3.5.5.2
g/dL
---.. -.e/di.
CARDIOVASCULAR/LIPIDS "--
4.5
08/30/2017
1RVAW:felY"'
Cholesterol
iTriayearides
NOL CHOL., DIRECT
MK as % of cholesterol
13 •
>la
•.•
•
it Evaluation: MOVE AVO.(PODERATE RISK)
:Chol/HDL Ratio
7.7 •
<7.4
Evaluation: ABOVE 4vG.(RODERATE RISK)
rlDIVA0L Aiii0 " -
0.0L%Chelestendk
. can't calc
Can't Cili
<100
<3.50
iiT&--
Cortrinta
- ::13:::71.
,
iNON.HDL CHOLESTEROL
195 HZ
<130
•
.
.
.
.
i. ISSTEit:imable to calculate 101 dojos a Triglyceride lent of greater then 400agidt,
•
•
•
•
•
. .
•
.0.6C—CALCULATED
Can't Calc
7-32
mg/dL
f
Can't adc TOSV2017
doe
<150
>40
ragiar.
.471
S at
HZ
mg/dL
mg/dL
TRIP
'INP
•
MP
08/30/2017
0E/30/2017 :
08/30/2017
08/3437Trir2
1
1 08/3e/2917.,
can't Calc: One or more components was outside the measurable
range. We are unable to calculate.
794
THVROXINE(T4)
1.770
SioReference Laboratories, Inc.
481 Edward H. Ross OP I elmmoon Park. N/07487 I
0.178-4.530
u1U/aL
4.9.121
ustiE
08/30/2017
EN/30/3017
James Weisberger M.D.
Page 1 of
4
Laboratory Director
printed 09/19/2017 11:48
EFTA00299761
BioReference
ABORATORiES
er OPKO Hecon Convene
ORSHER, STUART
3078 - STUART ORSHER, M.D.
9 EAST 79TH ST,
NEW YORK, NY 10021
Acct #: (03870)
P.
CLINICAL REPORT
MO
EPSTEIN, JEFFREY
-----)
DOB: 01/26/1953 Age: 64 V Six: M
U/Fl:
Bed:
Rm:
Patient ID:
Address:, EAST Tut STREET,
NEW YORK, NY 10021
11:
-- eve
IM a
bodies say occasionally pees ct for more than 12
--months post-infection.
i --Test developed and characteristics determined by ARDS
Laboratories. See Compliance Statement A: eruplab.com/Cs
--www.aruplab.com, lull.° Delgado, MD - Lab. Director
• B. quintana Ab, IgG
<1:64
i --INTERPRETIVE MS092447104: Bartonella quintana Antibody, IgG
Less than 1:64
Negative: No significant level of
I ..
Bartonella quintana XgG antibody
detected.
;
1:64 - 1:123
Equivocal: Questionable presence
of Bartonella quintana IgG
antibody detected. Repeat tasting
in 10-14 days may be helpful.
:•
1466 or greater
Positive: Presence of /6
--
antibody to Bartonella quintana
detected, suggestive of current
or past infection.
. --A IOW:positive suggests past exposure or infection, while high
--positive results may indicate recent or current infection, but is
--inconclusive. for diagnosis. Seroconversion between acute and
-=convalescent sera is considered strong evidence of recent
; -infection. The best evidence for infection is a significant change
two appropriately timed specimens where both tests are done in
--the same laboratory at the same time.
--Test developed and characteristics determined by ARUP
--Laboratories. See Coepliance Statement A: aruplab.com/CS
Nip. dil.
Noe:
Reactive
0.03
Ab. (S/C0 RATIO)
! •
PerforMed by:
ARUP
500 Chipeta Nay
Salt Lake City, UI 8.41013
Hepatitis B Result Interpretation
(for reference use only)
NOD-Riective .
41.80
Marker
See.
Li/EA*
Acute
Past
Chronic
RSV
issAg
+
+
+
NBeAe
+
+
+/-
NIP.B.,CORE A6,IgM
+
-
tRIP.ECORE AB.
+
+
+
Warn:
+/-
+/-
.
+/-
+
*LateIntileation/Early Acute
NOTE: In remote past infection, H9sAb level may be Negative or
BioReference laboratories, Inc.
481 Edward H. Ross D- I Elmwood Park. N) 07407
PRELIMINARY
Specimen ID: 104659439
Date Of Report: 09/19/2917 05:29
Date Collected: 09/15/2017 08:57
Date Received: 09/15/2017 23:06
North America Eastern 7itte
JarnesWeiabergorld.D.
Page 3 of
4
Laboratory Director
Printed 09/19/2017 11:48
EFTA00299762
BioReference
PRELIMINARY
: Al:ORATORI
ES
an OPKO HasIth Company
ORSNER, STUART
C3070 - STUART ORSHER, M.D.
9 EAST 79TH ST.
NEW YORK, NY 18021
Ct 8: (C3070)
P:
CLINICAL REPORT
EPSTEIN, iEFFREY
DOB: 01/20/1953 Ago: 64 V Sex: M
/FL:
Bed:
Patient xo:
Address:9 EAST 71ST STREET,
NEW YORK, NY 20021
FOLIC ACID
7.77
Tap
-101110/i617—
..
>5.38
Folic Acid Range
Units (ng/mli
Normal
>5.38
Borderline deficient
3.38.5.38
Deficient
0.35-3.37
Excessive
>24.00
359
.150K, IfITEX/N D
_
.
.
: VITAMIN 0,25-00 TEST INFORMATION
Range (ng/mL)
<20.0
20.0-31.9
32.0-100.0
>100.8
'Mt
"'
INTACT
;Aiuko-nb T Oi b (58)
ArTgi, —
Alkupt Ab tipe 8 (si)
PNEUMO AD TYPE 9 (9N) (58)
(*MSC 0 TYPE 12 (12P) (58)
ifsNEUMO Ab TYPE 14 (58)
* OrimUMO-A*O-ttOkii* (IOW (51) *
41**(23)** (MO'
I
Specimen ID: 104659439
Date Of Report: 09/19/2017 05:29
Date Collected: 09/15/2017 08:57
Date Received: 09/15/2017 23:06
North asertco foster,' nee
. .
31.8 LO
nth&
Suggested Interpretation
Deficient
Insufficient
Sufficient
Possible Adverse Effects
52.0 '
19.9-7.4
pest
106.0 HI
13.8-85.0
pg/mL
TO POLE
TO FOLLOW
-16
TO FOLLOW
TO FOLLOW
TO FOLLOW
TO FOLLOW
TO FOLLOW' -
ro POLLai
PNEUMO Ab TYPE 26 SO tss) to OoLLow
PNEUMO Ab TYPE 5'(58)
TO FOLLOW
PNEUMO Ab TYPE Si (7F) (58)."
000•61
IFINEUND'Ab TYPE 56: (18C) (58)
TO FOLLOW
;ONEOMO ii*,*tyPE
(58)
TO
t
i4ense5i-Triirar
Ab (3)
TO FOLLOW
•
•
.
<0.3 LO
4.4 --
0.4 Le
0.4 LO
(0.3 LO
23.2
8.8 LO
48;3 LO
8.5 lo
7.8
is
1.3 LO
0.4 LO •
96/30/2017
08/34/2017
OBA7/5317 :
08/30/2017
00/30/2017
08/30/2017
00/30/2017
08/30/2017
eniSehr
ea/se/atir:
08/30/2017
08/30/2817
06/30%2017
08/30/2017
08/30/2017
NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results.
Please resubmit a fasting specimen at your earliest convenience.
sloReference Laboratories, Inc.
481 Edward H. Ross Dr I Elmwood Park, NT 07407 I
ea/seneii
JnosembYelebergmrhILD.
Page 4 of
4
LaboratoryDirector
Printed 09/19/2017 11:48
EFTA00299763
EFTA00299764
Technical Artifacts (8)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
aruplab.comDomain
eruplab.comDomain
www.aruplab.comIPv4
3.38.5.38IPv6
13::Phone
2447104Phone
4659439Wire Ref
referenceForum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.